BRPI0507856A - composição farmacêutica, e, processo para preparar o anticorpo abeta - Google Patents
composição farmacêutica, e, processo para preparar o anticorpo abetaInfo
- Publication number
- BRPI0507856A BRPI0507856A BRPI0507856-3A BRPI0507856A BRPI0507856A BR PI0507856 A BRPI0507856 A BR PI0507856A BR PI0507856 A BRPI0507856 A BR PI0507856A BR PI0507856 A BRPI0507856 A BR PI0507856A
- Authority
- BR
- Brazil
- Prior art keywords
- preparing
- pharmaceutical composition
- abeta antibody
- abeta
- free
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54676404P | 2004-02-23 | 2004-02-23 | |
| PCT/US2005/005198 WO2005082939A2 (en) | 2004-02-23 | 2005-02-17 | Anti-abeta antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0507856A true BRPI0507856A (pt) | 2007-07-10 |
Family
ID=34910810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0507856-3A BRPI0507856A (pt) | 2004-02-23 | 2005-02-17 | composição farmacêutica, e, processo para preparar o anticorpo abeta |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20070190046A1 (https=) |
| EP (1) | EP1720909B1 (https=) |
| JP (1) | JP4851348B2 (https=) |
| KR (2) | KR100889430B1 (https=) |
| CN (1) | CN1922209B (https=) |
| AT (1) | ATE534667T1 (https=) |
| AU (1) | AU2005217596B2 (https=) |
| BR (1) | BRPI0507856A (https=) |
| CA (1) | CA2556436C (https=) |
| CY (1) | CY1112162T1 (https=) |
| DK (1) | DK1720909T3 (https=) |
| EA (1) | EA009872B1 (https=) |
| ES (1) | ES2375627T3 (https=) |
| IL (1) | IL177611A (https=) |
| NO (1) | NO20064239L (https=) |
| PL (1) | PL1720909T3 (https=) |
| PT (1) | PT1720909E (https=) |
| SI (1) | SI1720909T1 (https=) |
| UA (1) | UA93181C2 (https=) |
| WO (1) | WO2005082939A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
| HRP20140240T4 (hr) | 2005-11-30 | 2017-02-24 | Abbvie Inc. | Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba |
| EP1959996A2 (en) | 2005-12-12 | 2008-08-27 | AC Immune S.A. | Monoclonal antibody |
| EP2046833B9 (en) | 2006-07-14 | 2014-02-19 | AC Immune S.A. | Humanized antibody against amyloid beta |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| WO2008081008A1 (en) | 2007-01-05 | 2008-07-10 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
| TW200844110A (en) | 2007-01-11 | 2008-11-16 | Univ Marburg Philipps | Diagnosis and treatment of alzheimer's disease and other neurodementing diseases |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| BRPI0818623A2 (pt) * | 2007-10-05 | 2017-05-23 | Ac Immune Sa | composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal |
| AU2008311367B2 (en) | 2007-10-05 | 2014-11-13 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| AU2009319864A1 (en) | 2008-11-25 | 2011-07-14 | Biogen Idec Ma Inc. | Use of DR6 and P75 antagonists to promote survival of cells of the nervous system |
| CN102317316B (zh) | 2008-12-19 | 2014-08-13 | 帕尼玛制药股份公司 | 人抗α突触核蛋白自身抗体 |
| US20110110942A1 (en) | 2009-11-12 | 2011-05-12 | Genentech, Inc. | Method of promoting dendritic spine density |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| EP2598882B1 (en) | 2010-07-30 | 2017-07-26 | AC Immune S.A. | Safe and functional humanized antibodies for use in treating an amyloidosis |
| PL3042917T3 (pl) * | 2010-08-12 | 2018-07-31 | Eli Lilly And Company | Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| SI2723379T1 (sl) | 2011-06-23 | 2019-03-29 | Biogen International Neuroscience Gmbh | Molekule, ki se vežejo ma anti alfa-sinuklein |
| US20150209406A1 (en) | 2012-09-07 | 2015-07-30 | Massachusetts Eye And Ear Infirmary | Methods and compositions for regenerating hair cells and/or supporting cells |
| US20150209367A1 (en) | 2012-09-07 | 2015-07-30 | Massachusetts Eye & Ear Infirmary | Treating Hearing Loss |
| CN120904322A (zh) | 2013-09-13 | 2025-11-07 | 豪夫迈·罗氏有限公司 | 包含纯化的重组多肽的方法和组合物 |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| JP6840774B2 (ja) | 2016-05-16 | 2021-03-10 | ザ ジェネラル ホスピタル コーポレイション | 肺上皮エンジニアリングにおけるヒト気道幹細胞 |
| US20210355138A1 (en) * | 2016-08-11 | 2021-11-18 | Eli Lilly And Company | Aminothiazinies and their use as bace1 inhibitors |
| CN118370815A (zh) | 2017-08-22 | 2024-07-23 | 渤健马萨诸塞州股份有限公司 | 含有抗β淀粉样蛋白抗体的药物组合物 |
| TWI843040B (zh) | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| CA3243602A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0001232A3 (en) | 1996-12-23 | 2001-02-28 | Elan Pharmaceuticals Inc San F | Cycloalkyl, lactam, lactone derivatives and their thio analogues inhibiting betha-amyloid peptide release and/or its synthesis and pharmaceutical compositions containing the compounds |
| US6518011B1 (en) * | 1999-01-13 | 2003-02-11 | Bristol-Myers Squibb Company | Method for screening compounds to identify beta-amyloid production modulators |
| DE1257584T1 (de) * | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| JP2003530437A (ja) * | 2000-04-13 | 2003-10-14 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | Ａβ４２低下物質 |
| PE20020574A1 (es) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| EP2165714B1 (en) * | 2001-04-30 | 2013-10-23 | Eli Lilly And Company | Humanized antibodies recognizing the beta-amyloid peptide |
-
2005
- 2005-02-17 SI SI200531422T patent/SI1720909T1/sl unknown
- 2005-02-17 PL PL05723280T patent/PL1720909T3/pl unknown
- 2005-02-17 EA EA200601545A patent/EA009872B1/ru not_active IP Right Cessation
- 2005-02-17 DK DK05723280.3T patent/DK1720909T3/da active
- 2005-02-17 EP EP05723280A patent/EP1720909B1/en not_active Expired - Lifetime
- 2005-02-17 ES ES05723280T patent/ES2375627T3/es not_active Expired - Lifetime
- 2005-02-17 JP JP2006554230A patent/JP4851348B2/ja not_active Expired - Fee Related
- 2005-02-17 KR KR1020067016812A patent/KR100889430B1/ko not_active Expired - Fee Related
- 2005-02-17 US US10/590,411 patent/US20070190046A1/en not_active Abandoned
- 2005-02-17 WO PCT/US2005/005198 patent/WO2005082939A2/en not_active Ceased
- 2005-02-17 UA UAA200609258A patent/UA93181C2/ru unknown
- 2005-02-17 CA CA2556436A patent/CA2556436C/en not_active Expired - Fee Related
- 2005-02-17 KR KR1020087031635A patent/KR20090005410A/ko not_active Ceased
- 2005-02-17 PT PT05723280T patent/PT1720909E/pt unknown
- 2005-02-17 AU AU2005217596A patent/AU2005217596B2/en not_active Ceased
- 2005-02-17 AT AT05723280T patent/ATE534667T1/de active
- 2005-02-17 BR BRPI0507856-3A patent/BRPI0507856A/pt not_active IP Right Cessation
- 2005-02-17 CN CN2005800056858A patent/CN1922209B/zh not_active Expired - Fee Related
-
2006
- 2006-08-21 IL IL177611A patent/IL177611A/en not_active IP Right Cessation
- 2006-09-19 NO NO20064239A patent/NO20064239L/no not_active Application Discontinuation
-
2011
- 2011-12-21 CY CY20111101276T patent/CY1112162T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1922209B (zh) | 2012-09-05 |
| AU2005217596A1 (en) | 2005-09-09 |
| CA2556436A1 (en) | 2005-09-09 |
| KR20060126785A (ko) | 2006-12-08 |
| PT1720909E (pt) | 2011-12-23 |
| US20070190046A1 (en) | 2007-08-16 |
| DK1720909T3 (da) | 2012-01-30 |
| JP2008500279A (ja) | 2008-01-10 |
| JP4851348B2 (ja) | 2012-01-11 |
| CY1112162T1 (el) | 2015-12-09 |
| EP1720909A2 (en) | 2006-11-15 |
| WO2005082939A2 (en) | 2005-09-09 |
| EA200601545A1 (ru) | 2007-02-27 |
| WO2005082939A3 (en) | 2005-10-27 |
| KR20090005410A (ko) | 2009-01-13 |
| IL177611A (en) | 2013-05-30 |
| EA009872B1 (ru) | 2008-04-28 |
| CA2556436C (en) | 2014-04-01 |
| EP1720909B1 (en) | 2011-11-23 |
| KR100889430B1 (ko) | 2009-03-23 |
| ES2375627T3 (es) | 2012-03-02 |
| AU2005217596B2 (en) | 2012-01-19 |
| PL1720909T3 (pl) | 2012-04-30 |
| SI1720909T1 (sl) | 2012-01-31 |
| NO20064239L (no) | 2006-11-20 |
| UA93181C2 (ru) | 2011-01-25 |
| ATE534667T1 (de) | 2011-12-15 |
| CN1922209A (zh) | 2007-02-28 |
| IL177611A0 (en) | 2006-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0507856A (pt) | composição farmacêutica, e, processo para preparar o anticorpo abeta | |
| NO20083895L (no) | Anti-IGF-1R human monoklonalantibody formulering | |
| TW200745161A (en) | Stable antibody formulation | |
| CU20120095A7 (es) | Antagonistas de pcsk9 | |
| CY2018013I2 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| CY1119106T1 (el) | Αντισωματα εναντι masp-2 | |
| CL2011000010A1 (es) | Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende. | |
| CL2010000426A1 (es) | Anticuerpo humano que se une al ligando para el ox40 (ox40l o gp34) humano; metodo de produccion; y composicion farmaceutica que lo comprende (div. sol. n°2389-05). | |
| CY1109010T1 (el) | γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ | |
| CY1111896T1 (el) | Απαραβιαστες φαρμακευτικες μορφες δοσολογιας δια του στοματος περιλαμβανουσες ενα οπιουχο αναλγητικο | |
| CO5720212A1 (es) | Composicion de anticuerpo her2 | |
| CY1118007T1 (el) | Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων | |
| NO345046B1 (no) | Oral doseringsform | |
| AR057807A1 (es) | Formulaciones de anticuerpo anti-cd3 | |
| CY1110026T1 (el) | Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων | |
| CY1110225T1 (el) | Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης | |
| MA30153B1 (fr) | Anticorps anti-ox40l et methodes correspondantes | |
| CY1109916T1 (el) | Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις | |
| BRPI0510043A (pt) | método de tratamento de dor neuropática usando antagonista de receptor crth2 | |
| DK1572087T3 (da) | Antistoffer med cancerantigen TMEFF2 og anvendelser deraf | |
| BRPI0508610A (pt) | derivados de aminoácidos | |
| BRPI0508064A (pt) | flavivìrus, composição de vacina e molécula de ácido nucléico | |
| EA200700702A1 (ru) | Аналоги локсапина и способы их применения | |
| EA200801174A1 (ru) | Антитела-миметики glp-2, полипептиды, композиции, способы и применения | |
| EA200601743A1 (ru) | Выделенный полипептид реналазы и его применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 12A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |